**Author details**

Sanja Klobučar Majanović1,2, Olga Cvijanović Peloza3 \*, Dijana Detel4 , Gordana Kenđel Jovanović5 , Miro Bakula6,7, Dario Rahelic7,8,9, Tea Čaljkušić Mance10,11, Tamara Šoić Vranić3 and Sanja Zoričić Cvek3

1 Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Centre Rijeka, Rijeka, Croatia

2 Department of Internal Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

3 Department of Anatomy, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

4 Department of Chemistry and Biochemistry, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

5 Department of Health Ecology, Teaching Institute of Public Health of Primorsko-goranska County, Rijeka, Croatia

6 Department of Endocrinology, Diabetes and Metabolic Disorders, Clinical Hospital "Sveti Duh", Zagreb, Croatia

7 School of Medicine, University of Zagreb, Zagreb, Croatia

8 Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia

9 School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia

10 Department of Ophtalmology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

11 Clinical Hospital Centre Rijeka, Rijeka, Croatia

\*Address all correspondence to: olga.cvijanovic@uniri.hr

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**17**

*Dyslipidemia: Current Perspectives and Implications for Clinical Practice*

[9] Liou L, Kaptoge S. Association of small, dense LDL-cholesterol

concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241993.

[10] Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV,

Lipoprotein as Biomarker for

Longev. 2017;2017:1273042.

2010;31:2844-2853.

mechanism of action of an enigmaticlipoprotein. Current

[14] Ference BA, Graham I,

Cardiol 2018;72:1141-1156.

2014;25:452-460.

Orekhov AN. Small Dense Low-Density

Atherosclerotic Diseases. Oxid Med Cell

[11] Rye KA, Barter PJ. Cardioprotective functions of HDLs. Journal of Lipid Research. 2014;55(2):168-179.

[12] Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. European Heart Journal.

[13] Koschinsky ML. Lipoprotein(a) and atherosclerosis. New perspectives on the

Atherosclerosis Reports. 2005;7:389-395.

Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll

[15] Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol.

[16] Boren J, Williams KJ. The central role of arterial retention of cholesterolrich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016;27:473-483.

[17] Lara-Guzman OJ, Gil-Izquierdo A, Medina S, et al. Oxidized LDL triggers

*DOI: http://dx.doi.org/10.5772/intechopen.98386*

[1] Roth GA, Mensah GA, Fuster V. The Global Burden of Cardiovascular Diseases and Risks. Journal of the American College of Cardiology,

[2] Yusuf S et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 highincome, middle-income, and lowincome countries (PURE): A prospective cohort study. Lancet 2019;395(10226):795-808.

[3] Fahy E, Cotter D et al. Lipid classification, structures and tools. Biochim Biophys Acta. 2011; 1811(11):

[4] Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT,

[5] Li Y, Hruby A, Bernstein AM, Ley SH, et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol.

2000;1488(3):189-210.

2015;66(14):1538-1548.

[6] Tomkin GH, Owens D. The chylomicron: Relationship to

of atherosclerosis by human chylomicron remnants. Journal of Atherosclerosis and Thrombosis.2

Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. European Journal of Epidemiology.

003;10(3):132-139.

[8] Nordestgaard BG,

1992;8(Suppl 1):92-98.

atherosclerosis. International Journal of Vascular Medicine. 2012;2012:784536.

[7] Wilhelm MG, Cooper AD. Induction

Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta.

**References**

637-647.

2020;76(25):2980-2981.

*Dyslipidemia: Current Perspectives and Implications for Clinical Practice DOI: http://dx.doi.org/10.5772/intechopen.98386*
